In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:

Optimal KRAS mutation testing
Emerging multiselective RAS inhibitors
Combination strategies

Presenters:

Nilofer Azad, MD, FASCO
Professor of Oncology
Associate Director of Clinical Research
Sidney Kimmel Cancer Center at Johns Hopkins University
Co-Leader, Developmental Therapeutics Clinical Trials Group
Baltimore, Maryland

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
UCLA School of Medicine
Los Angeles, California

Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc.

Link to full program:
https://bit.ly/4avdRZK

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer